{"title":"Efficacy and Safety of Ciprofol for Anesthesia in Painless Colonoscopy with Varying Body Mass Indices Patients: A Prospective, Single-Center, Observational Study.","authors":"Yaqi Li, Mailong Yuan, Ping Zhang, Tao Zhou, Mingsheng Zhang, Jinhui Xu","doi":"10.2147/DDDT.S496783","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ciprofol, a novel intravenous anesthetic derived from propofol, exhibits high lipophilicity. Its pharmacokinetics and pharmacodynamics may vary across different body mass indices (BMI) categories, but data on its optimal dosing as well as its safety and efficacy during colonoscopy anesthesia in varying BMI groups are lacking.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of ciprofol during anesthesia for painless colonoscopy in patients with varying BMI, and to explore the correlation between BMI and induction dose.</p><p><strong>Methods: </strong>The BMI classification standard used in this study followed the criteria used in China. This prospective, single-center, observational study enrolled two hundred patients and they were divided into three groups with BMI: Group A (18.5-23.9 kg/m²), Group B (24-27.9 kg/m²), and Group C (28-39.9 kg/m²). Ciprofol was administered slowly (3 seconds per milliliter) until MOAA/S ≤1. Induction dose, additional ciprofol use, procedure duration, recovery time, vital signs, and adverse events were recorded.</p><p><strong>Results: </strong>The total induction dose was higher in Groups B and C than in Group A, with Group C receiving the highest dose (P<0.001). Dose per kilogram of TBW was lower in Groups B and C (P<0.001), while corrected body weight (CBW)-based dosing showed no significant difference between groups (P=0.287). There were no significant differences in procedure duration, recovery time, or adverse events among groups.</p><p><strong>Conclusion: </strong>Ciprofol is safe and effective for colonoscopy anesthesia across BMI groups, offering stable hemodynamics without prolonging recovery or increasing adverse events. CBW is a reliable dosing metric for overweight and obese patients.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"1-9"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707850/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S496783","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：异丙酚（Ciprofol）是一种新型静脉麻醉药，由丙泊酚衍生而来，具有很高的亲脂性。其药代动力学和药效学在不同体重指数（BMI）的人群中可能会有所不同，但目前还缺乏有关其最佳剂量以及在不同体重指数人群结肠镜麻醉过程中的安全性和有效性的数据：目的：评估环丙酚在不同体重指数患者进行无痛结肠镜检查麻醉期间的有效性和安全性，并探讨体重指数与诱导剂量之间的相关性：本研究采用的 BMI 分类标准与中国使用的标准一致。这项前瞻性、单中心、观察性研究共招募了 200 名患者，并将他们按体重指数分为三组：A组（18.5-23.9 kg/m²）、B组（24-27.9 kg/m²）和C组（28-39.9 kg/m²）。缓慢注射环丙酚（每毫升 3 秒），直至 MOAA/S ≤1。记录诱导剂量、额外使用的环丙酚、手术持续时间、恢复时间、生命体征和不良事件：结果：B 组和 C 组的总诱导剂量高于 A 组，其中 C 组的剂量最高（PC）：不同体重指数组的结肠镜检查麻醉使用环丙酚安全有效，可提供稳定的血流动力学，不会延长恢复时间或增加不良反应。对于超重和肥胖患者来说，CBW 是一个可靠的剂量指标。
Efficacy and Safety of Ciprofol for Anesthesia in Painless Colonoscopy with Varying Body Mass Indices Patients: A Prospective, Single-Center, Observational Study.
Background: Ciprofol, a novel intravenous anesthetic derived from propofol, exhibits high lipophilicity. Its pharmacokinetics and pharmacodynamics may vary across different body mass indices (BMI) categories, but data on its optimal dosing as well as its safety and efficacy during colonoscopy anesthesia in varying BMI groups are lacking.
Objective: To evaluate the efficacy and safety of ciprofol during anesthesia for painless colonoscopy in patients with varying BMI, and to explore the correlation between BMI and induction dose.
Methods: The BMI classification standard used in this study followed the criteria used in China. This prospective, single-center, observational study enrolled two hundred patients and they were divided into three groups with BMI: Group A (18.5-23.9 kg/m²), Group B (24-27.9 kg/m²), and Group C (28-39.9 kg/m²). Ciprofol was administered slowly (3 seconds per milliliter) until MOAA/S ≤1. Induction dose, additional ciprofol use, procedure duration, recovery time, vital signs, and adverse events were recorded.
Results: The total induction dose was higher in Groups B and C than in Group A, with Group C receiving the highest dose (P<0.001). Dose per kilogram of TBW was lower in Groups B and C (P<0.001), while corrected body weight (CBW)-based dosing showed no significant difference between groups (P=0.287). There were no significant differences in procedure duration, recovery time, or adverse events among groups.
Conclusion: Ciprofol is safe and effective for colonoscopy anesthesia across BMI groups, offering stable hemodynamics without prolonging recovery or increasing adverse events. CBW is a reliable dosing metric for overweight and obese patients.
期刊介绍：
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
